Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 18,748 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Breast Cancer
Interventions: paclitaxel, Trastuzumab, Pertuzumab, carboplatin, Breast surgery, AC; Drug · Procedure
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Freeze Dried Plasma in Healthy Volunteers
Interventions: Autologous Freeze Dried Plasma (FDP), Fresh Frozen Plasma (FFP); Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diphtheria
Interventions: S315, 0.9% Sodium Chloride (NaCl); Drug
Lead sponsor: MassBiologics; Other
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
Interventions: PF-08046049; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 27
States / cities: Los Angeles, California • Pasadena, California • San Francisco, California + 11 more

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: TY-2136b; Drug
Lead sponsor: TYK Medicines, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Providence, Rhode Island • Houston, Texas

Conditions: Prevention From Norovirus Infection
Interventions: Norovirus Bivalent Vaccine, Saline Comparator; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Rochester, New York + 2 more

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC V7, Stage IIA Prostate Cancer AJCC v7
Interventions: Behavioral Dietary Intervention, Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration; Behavioral · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 40 Years and older · Male only
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Liver Transplantation
Interventions: Normothermic Liver perfusion Device; Device
Lead sponsor: Cristiano Quintini; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Solid Tumours
Interventions: BMS-986517, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Irvine, California • Los Angeles, California • Orange, California + 6 more

Conditions: Tumors, Hodgkins Disease, Non-Hodgkins Lymphoma
Interventions: VLI; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Pharmacokinetics of Isavuconazole, Pharmacokinetics of S- and R-warfarin, Pharmacodynamics of Warfarin, Healthy Volunteers
Interventions: Isavuconazole, Warfarin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Lung Cancer
Interventions: RAD001, Docetaxel; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Neurofibromatosis Type 1
Interventions: Selumetinib granule formulation, Selumetinib capsule formulation; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Year to 6 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Akron, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more

Conditions: Healthy
Interventions: Danicopan, Cyclosporine, Tacrolimus, Calcium Carbonate, Aluminum/Magnesium Hydroxide/Simethicone, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Breast Cancer
Interventions: quality-of-life assessment; Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 0 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 224
States / cities: Fairbanks, Alaska • Phoenix, Arizona • Fairfield, California + 144 more

Conditions: Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma, Hepatocellular Carcinoma, Glioma, Sarcomatoid Carcinoma
Interventions: ADI-PEG 20; Drug
Lead sponsor: Polaris Group; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Covid19
Interventions: sotrovimab; Biological
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more

Conditions: Advanced Solid Tumor Malignancies
Interventions: PD-0332991, 5-FU, Oxaliplatin; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer
Interventions: filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody BrE-3, yttrium Y 90 monoclonal antibody BrE-3; Biological · Procedure · Radiation
Lead sponsor: Cancer Research Institute of Contra Costa; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 2
States / cities: San Francisco, California • Aurora, Colorado

Conditions: Advanced Solid Tumor
Interventions: NB004 tablets; Drug
Lead sponsor: Ningbo Newbay Technology Development Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: New Orleans, Louisiana • Houston, Texas

Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable Solid Neoplasm
Interventions: Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Topotecan Hydrochloride, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 15
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 11 more

Conditions: Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral
Interventions: Nilotinib; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Stanford, California • Denver, Colorado • Buffalo, New York + 1 more

Conditions: Hematologic Malignancies
Interventions: IPI-493; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Houston, Texas

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma With Failed Remission
Interventions: FOR46; Drug
Lead sponsor: Fortis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 4 more

Search by objective public record fields.

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

Ascending Doses of Autologous FDP vs FFP

Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

Norovirus Bivalent-Vaccine Efficacy Study

Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer

Pilot Study to Assess Safety and Feasibility of Normothermic Machine Preservation In Human Liver Transplantation

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects

Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Dose Escalation of IPI-493 in Hematologic Malignancies

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)